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SUMMARY On the ground of the evidentiated choleretic activity of 3-[2-
benzylbenzimidazol-l-yIJbutanoic acid, 28 new acids were prepared in order to evalu-
ate the influence of suitable substitutions in either C5 of heteroring or C3', C4', 
C5' of benzyl group in position 2 on the choleretic activity. Pharmacological results 
after i. v. administration of 0.5 mmollKg in rats confirmed a general high choleretic 
activity that in eleven cases showed during the first 4 hours an increase of bile volume 
higher than 80%, that is superior to that produced by dehydrocholic acid. Only in 
a few cases the bile volume increase was less than 37% of basal value. 
RIASSUNTO Sulla base dell'evidenziata attivita coleretica dell'acido 3-[2-
benzilbenzimidazol-l-iIJ-butanoico sono stati preparati 28 nuovi acidi recanti sosti-
tuenti nella posizione 5 del nucleo benzimidazolico e nelle posizioni 3', 4', 5' del 
benzile in 2 a/fine di valutarne I'effetto sull'attivita coleretica. L 'indagine farmaco-
logica effettuata su questi e aftri acidi gia descritti ha confermato, nel ratto alia do-
se di 0.5 mmollKg, una generale attivita coleretica che in undici casi comporta una 
variazione percentuale media del flusso biliare nelle quattro ore superiore all'80% 
e quindi superiore a quella dell'acido deidrocolico. Solo in pochi casi I'aumento del 
volume della bile resta 01 di sotto del 37%. 
(*) Part of this work was presented as poster communication at 6th National Mee-
ting of the Division of Medicinal Chemistry of the Societa Chimica Italiana, 
Alghero, 14-18 October 1986. 
(**) To whom correspondence should be addressed. 
22 G. GRELLA et al. 
Introduction 
In a previous paper (1) we reported that 3-[2-aryl-5-R-benzimidazol-l-
yl]-butanoic acids of structure A possess a generalised choleretic activity in 
• 





CH 3 -CH -CH 2-C0 2 H 
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X=CH; C-CH 3 ; C-Cl; C-OCH 3 ; C-OC 2 H5 ; 
R=H; Cl; Cf3 ; CO-CH 3 ; CH(OH)CH 3 ; N0 2 
N • , 
In several acids this activity was superior to that of 3-[benzotriazol-l-
yl]butanoic acid, which prompted our research in this field (2, 3), and to 
that of dehydrocholic acid (DCA) taken as reference. In that context we 
also remarked that, in accordance with preliminary observations of Prezio-
si (4), compound B was a quite potent choleretic among a series of 3-




CH 3-CH-C'H 2 -C0 2 H 
B 
Actually the acid B showed a persistently high choleretic activity du-
ring the first three hours after i. v. administration. On the basis of these en-
couraging results we have now designed a new series of acids (5-34) with 
the same structure of B where we considered the effect of further substitu-
tions in either position 5 of the heterocycle or in position 3',4',5' of benzyl 
group attached in position 2 and for which we have evaluated the choleretic 
activity in comparison with DCA and B. 
In order to support further the importance of an aromatic moiety on 
position 2 of the benzimidazole ring for the choleretic activity we have also 
tested the compounds 35-36, previously described (4), as well as some pre-
• 
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cursors (2c, 3a, 3c) of Scheme 1 and the simple 3-aminobutanoic acid (ABA), 










The preparation of the set of acids listed in Table I was achieved through 
the known King and Acheson's procedure (5) previously used in similar ca-
ses (6) and reproduced in Scheme 1. The condensation of o-phenylen-
diamines with the corresponding iminoether hydrochlorides was carried out 
• 
in dry methanol and the expected acids 5-34 were obtained in fair yields. 
Most of the required o-phenylendiamines 3 were previously described (1,4,7). 
However, two additional derivatives (3a,f) were purposely prepared using 
the sequence of reactions of Scheme I. The suitable o-fluoronitrobenzenes 
were successfully reacted in isobutan-I-ol to obtain the intermediates (2a,f), 
while the corresponding chloroderivative failed to give the desired com-
pounds. All iminoether hydrochlorides, prepared according to previously 
reported procedures (6), were isolated as crystalline solids and their mp's 
• 
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• SCHEME 1 
i,isobutanol; H, H jPd; iii, NH /H S in ethanol; iv, dr y methanol; v, Acetic anhydride. 
2 3 2 
are given for the first time. The starting nitriles were all but one available 
on the market. p-Ethoxy-phenylacetonitrile was prepared as indicated in ref. 
(6). Compound 10 was obtained by catalytic hydrogenation of 9 and on ace-
tylation with acetic anhydride gave the acid 11. Physical properties and yields 
of all the prepared acids are reported in Table l. The structures of all the 
TABLE I 
Physical properties and yields of 3-[2-(3, 4, 5-trisubstituted)benzyl-5-R-benzimidazol-l-yl]b utanoic acids. 
Comp. R R' R" R'" M.P. °C Yield "70 Analysis for (C, H, N) Amaxnm (log 8)·95"70 EtOH 
B H H H H 175-178 79 (a) 283{3.83), 276(3.80), 253{3.86) 
5 H H CH3 H 195-96 73 C19H20N202 + 0.5H2O 283{3.78), 276{3. 72), 253{3.66) 
6 H H Cl H 170-72 96 (b) -
7 H H OCH3 H 190-92 74 (c) 283{4.03), 276(3.99), 253{3.97) 
8 H H OC2HS H 200-02 69 C20H22N203 + 0.40H2O -
9 H H N02 H 225-30 83 ClsH17N304 + 0.IOH2O -
10 H H NH2 H 125-30 78 (d) ClsHl9N302 + 1.30H2O -
11 H H NHCOCH3 H 145 64 (e) C20H21N303 + 1.20H2O -
12 H OCH3 OCH3 H 145 73 C2oH22N204 284(4.04), 277(4.00), 255sh{3.93), 234{4.06) 
13 H OCH3 OCH3 OCH3 208-10 83 C21H24N20S -
14 COCH3 H H H 204-07 73 C2oH20N203 -
15 COCH3 H CH3 H 98-103 57 C21HnN203 + 0.50H2O -
16 COCH3 H Cl H 200 50 C20H19N203Cl + 0.IOH2O -
17 COCH3 OCH3 OCH3 H 222-27 46 Cn H24N20 s + 0.25H2O -
18 CF3 H H H 168-70 74 Cl9H17N202F3 -
19 CF3 H CH3 H 185-90 72 C2oHl9N202F3 283{3.92), 277(3.87), 255{3.85) 
20 N02 H H H 175-80 57 ClsH17N304 -
21 N02 H CH3 H 195-200 71 Cl9Hl9N304 -
22 N02 H OC2Hs H 180-85 80 C20H21N30S -
23 Cl H H H 207-09 41 ClsHl7N202Cl + 0.IOH2O -
24 Cl H CH3 H 157-58 60 Cl9Hl9N202Cl + 0.75 H2O -
25 Cl H Cl H 175 84 ClSHl6N202Clz -
26 Cl H OC2HS H 168-70 69 C2oH21N203Cl + 0.30H2O -
27 Cl H N02 H 210-12 55 ClsHl6N304Cl -
28 Cl OCH3 OCH3 H 193-95 66 C20H21N204Cl -
29 CH3 H H H 178-80 66 C19H20N202 -
30 CH3 H CH3 H 170-72 78 C20Hn N20 2 + 0.30H2O -
31 CH3 H OCH3 H 160-62 85 C20Hn N20 3 + 0.35H2O -
32 CH3 H OC2H S H 200-05 65 C21H24N203 + 0.30H2O -
33 CH3 H N02 H 198-200 71 Cl9Hl9N304 -
34 CH3 OCH3 OCH3 H 163-65 79 C21H24N204 291{3.90), 282(3.95), 256sh(3.87), 234sh{4.0I) 
--
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compounds described are supported by elemental analyses (C,H,N) and spec-
troscopical data. IR spectra were not characteristic and showed an absorp-
tion between 1710-1695 cm - 1 due to acid carbonyl. UV spectra in ethanol 
exhibited two sharp absorption maxima in the range 291-283 and 282-276 
nm in accordance with the literature data for 2-alkylbenzimidazoles (8, 9). 
These maxima become broad when electronwithdrawing substituents are pre-
sent in the position' 5 of benzimidazole. A few examples are reported in Ta-
ble I. 
IH-NMR spectra at 200 MHz in CDCl] or DMSO-d6 are very similar, 
resonances due to aromatic protons being well defined as well as those of 
the aliphatic chain. Benzylic methylene protons can appear either as singlet 
or as an AB system because of the non equivalence arising from free rota-
tion of the phenyl ring. A typical spectrum of this class of compounds is 
reported for the acid 34: 
oH200 MHz (CDCl]): 7.46 (s, IH, C-4 H), 7.34 (d, IH, J 8.3, C-7 H), 
7.03 (d, 1 H, J 8.3, C-6 H), 6.75 (s, I H, C-6' H), 6.70 (s, 2H, C-2', 5' H), 
5.08 (m, IH, N-CH), 4.41 (s, 2H, C-2 CH,), 3.80 (s, 3H, C-3' OCH3) , 3.73 
(s, 3H, C-4' OCHJ), 3.13 (dd, IH, J 16.4 and 9.9, CH,COOH), 2.78 (dd, 




Melting points were taken on a Kofler apparatus and are uncorrected. IR spec-
tra are from nujbl mulls and were recorded on Perk in-Elm er 781 spectrophotometer. 
UV spectra are in nm for ethanolic solutions and were reCOrded with Perkin-Elmer 
Lambda 5 instrument. IH-NMR spectra are in ppm (0) and were recorded with a 
Varian XL-2oo instrument. Elemental analyses were performed at Laboratorio di 
Microanalisi, Dipartimento di Scienze Farmaceutiche, University of Padova, and 
the results were within ±0.4070 of the theoretical values for C,H,N. 
Intermediates 
Most o-phenylendiamines (3) of Scheme 1 were known (1,4, 7) and were repre-
pared. Compounds 3a,f not previously described were prepared as reported below. 
3-[(2-Nitro)anilinolbutanoic acid (2a) 
A mixture of 2-nitrofluorobenzene (27.2 ml, 258 mmol) and 3-amino-butanoic 
acid (ABA) (29.9 g, 290 mmol), in isobutyl alcohol (480 ml) and in the presence 
of triethylamine (TEA) (35.3 ml, 253 mmol) was heated under reflux for 24 h. After 
evaporation of the solvent in vacuo the oily residue was taken up with I M NaOH 
aqueous solution (300 ml) and then extracted with diethyl ether. On acidification 
of the alkaline solution with 6M HCI aqueous solution a pure yellow-orange cry-
stalline compound 2a (42.6 g, 74070 yield) was obtained. Mp 98-100°C. Evaporation 
of the ethereal extract gave some starting 2-nitrofluorobenzene. 
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3-[(2-Nitro-4-methyl)anilino]butanoic acid (2f) 
In a similar manner from equimolar amounts (81.4 mmol) of 2-fluoro-5-
methylnitrobenzene (10.0 m\) and TEA (11.3 ml) and a slight excess of 3-
amino butanoic acid (9.44 g, 91.5 mmol), in isobutanol (150 ml), after cooling of 
the reaction mixture some starting acid (2.4 g). was recovered by filtration and the 
work-up of the mother liquors as above gave deep yellow-orange crystals of 2f (8.6 
g, 44070 yield), mp 128-130°C. 
3-[(2-Amino)anilino]butanoic acid (3a) 
A solution of 2a (3.0 g, 13.4 mmol) in ethanol (60 ml) was hydrogenated under 
moderate pressure (2 at m) in the presence of 10070 palladium on charcoal (0.3 g); 
the hydrogen uptake was complete within 2 h. 
After filtration of the catalyst the ethanolic solution was concentrated in va-
cuo; a first crop of compound 3a (2.0 g; mp 135-38°C) was collected and on further 
concentration more 3a (0.3 g) was obtained, with an overall yield of 84%. 
3-[(2-Amino-4-methyl)anilino]butanoic acid (3f) 
This acid was obtained in 70% yield in a similar manner as above. Mp 118-120°C. 
Iminoether hydro chlorides (5g-o). General procedure 
A solution of equimolar amounts (28.4 mmol) of the suitable benzyl-cyanide 
and absolute ethanol in chloroform (30 ml) was saturated with dry hydrogen chlori-
de at 0-5°C and stopped. After two hour standing at room temperature the solvent 
was removed in vacuo without heating. The obtained solid was washed out twice 
with dry diethyl ether and dried in a dessicator. All iminoether hydrochlorides were 
obtained in good yield (>80%) as crystalline compounds with defined mp's (0C) 
as listed: Sg: 98; Sh: 124-126; Si: 128; Sk: 102-104; 51: 115-118; Srn: 195; 5n: 118; 
50: 128. 
Acids 5-9 and 12-34. General procedure 
A mixture of equimolar amounts (3.60 mmol) of o-phenylendiamine derivative 
3 and iminoether hydrochloride in methanol (10 ml) was stirred at room temperatu-
re for 1 h. Ring closure was complete after this time. The acids mostly precipitated 
and were collected: sometimes to induce precipitation an equal volume of water was 
added to the methanol solution. On concentration of the mother liquors or by fur-
ther adding of water more acid was obtained. A thorough washing of the precipita-
tes with water was sufficient to obtain pure compounds, which were analysed wi-
thout further purification. 
3-[2-(4-Amino)benzylbenzimidazol-I-yl]butanoic acid (10) 
Compound 9 (2.3 g, 6.76 mmol), dissolved in a mixture of a 5% sodium hydro-
gen carbonate aqueous solution (11.4 ml, 6.78 mmo\) and ethanol (92 m\), was hy-
drogenated in the presence of 10% palladised charcoal (0.23 g) at room temperatu-
re and under moderated pressure (2 atm) within 2 h. After removal of the catalyst 
the solution was made neutral and evaporated in vacuo. The thick oily residue was 
triturated with water (30 ml) allowing the acid 10 to crystallize (1.64 g, 78% yield). 
3-[2-(4-A cetylamino)benzylbenzimidazol-I-yl]butanoic acid (11) 
A solution of compound 10 (1.50 g, 4.85 mmol) in acetic anhydride (1.4 ml) 
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was stirred at 65°C for 10 min. On cooling, water (12 ml) was added and the mixtu-
re re-heated at 65°C for 5 min. A precipitate was collected and thoroughly washed 
with water to give pure 11 (1.39 g, 820;0 yield). 
B) PHARMACOLOGY 
Materials and methods 
Pharmacological testing was carried out for all the compounds listed in Table 
I and for the derivatives 35 and 36 previously described (4). In addition the interme-
diates 2a, 3a, 3c and 3-aminobutanoic acid were tested. Dehydrocholic acid (DCA) 
was taken as reference. The procedure used for the determination of choleretic acti-
vity was previously described (3). 0.1 M aqueous solutions of both sodium salts of 
the acids and DCA were used. 0.5 mmollKg (5 mllKg) was given by i.v. route to 
male Wistar-Morin weighing 300-420 g rats fed with Nossan synthetic feed. In one 
. . 
case (16) on account of the low solubility only 0.25 mmollKg was administered in 
the same volume of solution. In the case of the acids B, 5 and 12 a dose of 0.25 
mmollKg was given to check any dose-dependent activity, while for the acids 13, 
18 and 24 this dose was used because of an high mortality encountered at 0.5 
mmollKg. However this dose was still too toxic in the case of the acids 19 and 22; 
hence the dose was further reduced to 0.12 mmollKg in latter cases. The acids 25 
and 26, which gave 100% mortality at 0.5 mmollKg were not further investigated. 
Controls were given either 5 mllKg of physiological solution or 5 mllKg of 0.2 M 
sodium hydrogen carbonate aqueous solution. 
During the experiments animals were housed at 29°C. Each compound was te-
sted .over a number of animals varying from 4 to 7 (Table II). 
The dry residue of the excreted bile was determined for a limited number of 
acids which were considered as representative of high, medium and low activity (Table 
Ill). This was accomplished drying standard volumes of bile in the thermostated 
oven at 90°C to,constant weight. On the dry residue, at the indicated times, it was 
determined by UV photometric titration the amount of the given acid excreted with 
the bile. Standard ethanol solutions (100 ml) containing a weighed amount of dry 
residue were used each time. 
Comparison of extinction coefficient (log f) recorded at the highest wavelength 
maximum against a calibration curve previously obtained at established concentra-
tions at the same wavelength (Table I) of the examined compounds allowed us to 
determine the amount of acid associated with the bile excretion (Table IV). To be 
noted that the basal bile does not exhibit any absorption around 280-290 nm, thus 
allowing a reliable determination of benzimidazole derivatives contents. 
Result and discussion 
The volumes of the excreted bile and their percent variations at the in-
dicated times against the basal values are reported in Table 11. Fig. 1 shows 
the average percent variation for each compound within the considered ti-
me. A certain number of derivatives have shown to be too toxic at 0.5 
mmollKg (2c, 13, 18, 19, 22, 24, 25, 26) and 100% mortality of the animals 
was reached within 1-3 h after administration. 
TABLE 11 
Effects of the acids on bile output in rats in comparison with physiological solution, NaHC03 solution, DCA. 
Compound Dose Animals Volumes ml±S.D.) of bile output at times OJo variation of bile output at times OJo mean 
mmollkg N. Basal 1 h 2h 3 h 4h 1 h 2h 3 h 4h variation 
Physiol. sol. - 7 0.87 ±0.03 0.80±0.03 0.72±0.04 0.69±0.04 0.58 ±0.04 - 8.0 - 17.2 - 20.7 - 33.3 - 19.8 
NaHC03(O.2M) - 4 0.85 ±0.02 0.95 ±0.05 0.79±0.04 0.89±0.1I 0.47 ±0.06 + 11.8 - 7.1 + 4.7 - 44.7 - 8.8 
DCA 0.50 4 0.59±0.03 1.69±0.32 1.31 ±0.20 0.67 ±0.05 0.60±0.1O + 186.4 + 122.0 + 13.6 + 1.7 + 80.9 
ABA 0.50 6 0.75 ±0.05 0.64±0.04 0.62±0.03 0.72 ± 0.06 0.57 ±0.05 - 14.7 '- 17.3 - 4.0 - 24.0 - 15.0 
B 0.50 7 0.78 ±0.04 1.94±0.12 1.95 ±0.07 1.55 ±0.07 1.45 ±0.06 + 148.7 + 150.0 + 98.7 + 85.9 + 120.8 
B 0.25 5 0.59±0.05 0.99 ±0.07 1.22±0.05 0.89±0.05 0.82±0.06 + 67.8 + 106.8 + 50.8 + 39.0 + 66.1 
38 0.50 5 0.66±0.03 0.68 ±0.04 0.82±0.02 0.73 ±0.03 0.70±0.03 + 3.0 + 24.2 + 10.6 + 6.1 + 11.0 
3c 0.50 7 0.67 ±0.03 1.02±0.1O 0.78±0.05 0.73 ±0.04 0.61 ±0.04 + 52.2 + 16.4 + 9.0 - 9.0 + 17.2 
5 0.50 4 0.71 ±0.07 1.35 ±0.21 1.32±0.08 1.32±0.07 0.94±0.05 + 90.1 + 85.9 + 85.9 + 32.4 + 73.6 
5 0.25 6 0.61 ±0.02 1.16±0.05 1.20±0.04 0.84±0.04 0.60±0.03 + 90.2 + 96.7 + 37.7 - 1.6 + 55.8 
6 0.50 6 0.49±0.07 0.58 ±0.05 0.60±0.04 0.70±0.08 0.80±0.12 + 18.4 + 22.4 + 42.9 + 63.3 + 36.8 
7 0.50 7 0.65 ±0.05 1.39±0.13 1.28 ±O.IO 1.40±0.1I 0.99±0.05 + 113.8 + 96.9 + 115.4 + 52.3 + 94.6 
8 0.50 6 0.53 ±0.03 1.04±0.1I 1.26±0.07 1.13 ±0.09 0.85 ±0.07 + 96.2 + 137.7 + 113.2 + 60.4 +101.9 
9 0.50 5 0.62 ±0.07 1.14±0.12 1.47 ±O.IO 1.38 ±O.II 1.19±0.12 + 83.9 + 137.1 + 122.6 + 91.9 + 108.9 
10 0.50 5 0.59 ±0.01 0.95 ±O.IO 0.85 ±0.02 0.68 ±0.04 0.52±0.05 + 61.0 + 44.1 + 15.3 - 11.9 + 27.1 
11 0.50 5 0.44±0.10 0.89±0.14 0.83 ±0.09 0.84±0.12 0.52 ±0.06 + 102.3 + 88.6 + 90.9 + 18.2 + 75.0 
12 0.50 7 0.69 ±0.06 1.83 ± 0.16 1.85 ± 0.14 1.50±0.06 1.16±0.1O + 165.2 + 168.1 +117.4 + 68.1 + 129.7 
12 0.25 7 0.49±0.03 1.14±0.12 0.77 ±0.07 0.69±0.07 0.53 ±0.07 + 132.7 + 57.1 + 40.8 + 8.2 + 59.7 
13 (a) 0.25 6 (b) 0.87 ±0.09 0.98 ±0.23 1.12 ± 0.15 1.03±0.12 0.59±0.06 + 12.6 + 28.7 + 18.4 - 32.2 + 6.9 
14 0.50 5 0.91 ±0.13 1.32±0.17 1.48 ±0.09 1.19±0.1I 1.00±0.05 + 45.1 + 62.6 + 30.8 + 9.9 + 37.1 
15 . 0.50 6 0.98 ±0.08 1.60±0.08 1.65±0.19 1.48 ±0.05 1.26 ±0.03 + 63.3 + 68.4 + 51.0 + 28.6 + 52.8 
16 0.25 4 0.77 ±0.05 0.86±0.09 0.73 ±0.06 0.85 ±0.03 0.63 ±0.06 + 11.7 - 5.2 + 10.4 - 18.2 - 0.3 
17 0.50 7 0.63 ±0.03 1.23 ±O.IO 1.55 ±0.19 0.97 ±0.06 0.95 ±0.03 + 95.2 + 146.0 + 54.0 + 50.8 + 86.5 
. 
18 (c) 0.25 7 0.83 ±O.IO 0.93 ±0.09 1.05 ± 0.09 0.90±0.08 0.88 ±0.07 + 12.0 + 26.5 + 8.4 + 6.0 + 13.2 
19d •• 0.12 7 0.58 ±0.04 0.94±0.03 0.93 ±0.03 0.60±0.02 0.41 ±0.02 + 62.1 + 60.3 + 3.4 - 29.3 + 24.1 
20 0.50 5 0.61 ± 0.11 1.26±0.13 1.26±0.13 1.17±0.09 1.04±0.03 + 106.6 + 106.6 + 91.8 + 70.5 + 93.9 
(a) 1000/0 mortality at 0.5 mmollkg within 3 h after administration; (b) during the experiment two animals died 2 h after administration; (c) 100% 
mortality at 0.5 mmollkg within 2 h after administration; (d) 100% mortality at 0.5 mmollkg within I h after administration; (e) 50% mortality 


































(Continuation table II) 
Compound Dose Animals Volumes ml±S.D.) of bile output at times 1170 variation of bile output at times 1170 mean 
mmol/ kg N. • • Basal I h 2h 3 h 4h I h 2 h 3 h 4h vanatlOn 
21 0.50 6 (b) 0.93 ::0.10 1.04::0.09 1.54::0.17 1.53 ::0.27 1.18 ::0.05 + 11.8 + 65.6 + 64.5 + 26.9 + 42.2 
• 
22 (d) 0.12 7 0.66 ::0.02 0.78 ::0.03 0.94::0.04 0.76:f0.04 0.51 ::0.02 + 18.2 + 42.4 + 15.2 - 22.4 + 13.3 
23 0.50 5 0.65 ::0.06 1.24::0.08 1.09::0.15 1.13 ::0.18 1.05 ::0.05 -+ 90.8 + 67.7 + 73.8 +61.5 + 73.4 
24 (a) 0.25 6 0.69::0.04 0.80::0.08 0.74::0.06 0.54::0.06 0.44::0.04 + 15.9 + 7.2 -21.7 - 36.2 - 8.7 
27 0.50 4 0.59 ::0.07 0.67 ::0.04 0.76::0.05 0.80::0.04 0.79::0.06 + 13.6 + 28.8 + 35.6 + 33.9 + 28.0 
28 0.50 6 0.66::0.07 0.99::0.06 0.93 ::0.07 0.88::0.09 0.84::0.10 + 50.0 + 40.9 + 33.3 + 27.3 + 37.9 
29 0.50 7 0.70::0.07 1.09::0.10 1.30::0.12 1.27 ::0.10 1.07 ::0.09 + 55.7 + 85.7 + 81.4 + 52.9 + 68.9 
30 0.50 5 0.52::0.03 0.98::0.05 1.14::0.10 1.39::0.15 0.88 ::0.08 + 88.5 + 119.2 + 167.3 + 69.2 + 111.0 
31 0.50 5 0.56 ::0.04 1.14±0.23 1.19::0.07 1.02::0.14 0.87:: 0.11 + 103.6 + 112.5 + 82.1 + 55.4 + 88.4 
32 0.50 6 0.88 ::0.07 1.43 ::0.12 1.78::0.15 1.99::0.14 1.02 ::0.08 + 62.5 + 102.3 + 126.1 + 15.9 + 76.7 
33 0.50 6 0.66::0.05 1.44::0.09 1.79::0.11 1.63::0.15 1.19::0.14 + 118.2 +171.2 + 147.0 + 80.3 + 129.2 
34 0.50 6 0.56::0.05 1.39::0.15 1.15 ::0.12 1.02::0.14 0.68 ::0.08 + 148.2 + 105.4 + 82.1 + 21.4 + 89.~ 
35 0.50 7 0.66::0.07 0.86::0.05 0.70::0.04 0.79::0.05 0.61 ::0.05 + 30.3 + 6.1 + 19.7 - 7.6 + 12.1 
36 0.50 5 0.57 ::0.05 0.75 ::0.05 0.52::0.05 0.50::0.03 0.46::0.02 + 31.6 - 8.8 - 12.3 - 19.3 - 2.4 
-
.. _-
- -- - - - - - - -- -
(a) 100070 mortality at 0.5 mmollkg within 3 h after administration; (b) during the experiment two animals died 2 h after administration; (c) 100% 
mortality at 0.5 mmollkg within 2 h after administration; (d) 100% mortality at 0.5 mmollkg within I h after administration; (e) 50% mortality 













Effect of the acids B, 5, 7, 12, 19 and 34 on bile dry residue. 
Dose Animals Dry residue of bile (absolute mean values in mg) at indicated times Comp. (percent variations against basal value) 
mmollkg N 
Basal 1 h 2h 3 h 4h 
Phys. sol. - 7 24.4 21.6 (- 11.5) 18.7 (- 23.4) 16.3 (- 33.2) 13.8 (-43.4) 
NaHC03 - 4 27.5 27.7 (+ 0.7) 21.8 (- 20.7) 25.1(- 8.7) 13.7 (-50.2) 
DCA 0.50 4 19.5 59.8 (+ 206.7) 41.7 (+ 113.8) 17.7 (- 9.2) 17.0 (-12.8) 
B 0.50 7 26.7 43.1 (+ 61.4) 42.1 (+ 57.7) 34.4 ( + 28.8) 31.3(+17.2) 
5 0.50 4 26.0 39.7 (+ 52.7) 38.3 (+ 47.3) 35.6 (+ 36.9) 24.8 (- 4.6) 
7 0.50 7 22.9 41.6 (+ 81.7) 37.2 (+ 62.4) 41.3 (+ 80.3) 26.1 (+ 14.0) 
12 0.50 7 24.8 57.6 ( + 132.3) 56.8 (+ 129.0) 46.4 (+87.1) 34.8 (+ 40.3) 
19 0.12 7 18.0 25.9 (+ 43.9) 23.4 (+ 30.0) 15.0 (-16.7) 10.5 (- 41. 7) 
34 0.50 6 22.2 43.0 (+ 93.7) 34.0 (+ 53.2) 29.4 ( + 32.4) 19.7 (-11.3) 
(*) deduced of the amount of acids detected according to Table IV. 
010 mean % mean 
variation corrected 




+41.3 + 17.2 
+ 33.1 - 4.5 
+ 59.6 +24.1 
+97.2 + 32.6 
+ 3.9 -10.4 
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TABLE IV 
Evaluation of the excreted acids in the dry residue of bile. 
Compd Dose Pverage Quantity of acid (in mg) detected Total • 
-by U.V. titration at times(~) nnol/kg weigt"/rat (g) excreted excreted 
Tota 1 ccmpd 1 " 2 " 3 " 4 " 
acid acid during 
gi yen (mg) (mg) 4" 
334 
B 0.50 49.2 10.1 6.2 5.3 4.1 25.7 52.2 
• • 
5 0.50 310 12.2 11.6 10.0 5.3 39.1 B1.8 
47.8 
7 0.50 379 9.7 9.0 9.0 4.8 32.5 52.8 
61.5 
12 0.50 402 20.1 22.9 14.1 7.0 64.1 90.0 
71.2 
19 0.12 323 4.5 3.2 1.7 0.9 10.3 67.8 
15.2 
34 0.50 400 16.1 12.4 10.4 6.5 45.4 61.6 
73.7 
(~)These quantities were calculated assuming that the injected acids were excreted 
unchanged and using for each of them the extinction coefficient indicated in Table I. 
Some of these compounds were toxic even at lower dosage (Table 11) 
and the most toxic seems to be 19. For the remaining acids it is supposed 
that the lethal Close is quite far from that (0.5 mmol/Kg) used for choleretic 
activity determination, since the animals did not show any sign of suffering 
during the experiment and afterwards. 
From the results of Table II and Fig. I it is evident that eleven acids 
[in decreasing order of activity: 12,33, B, 30, 9, 8, 7, 20, 34, 31, 17] were 
significantly more active than DCA ( + 81070) and two (12,33) were superior 
to the model compound B (+ 121 %). Five acids (32, 11,5,23,29) were al-
most as active as DCA, with a bile output increase ranging from + 77 to 
+ 69%, while for other five (15, 21, 28, 14,6) the volume increase goes pro-
gressively down to + 37% of the basal value; the remaining acids showed 
poor activity or were completely inactive. 
Reducing the dose from 0.5 to 0.25 mmollKg, the activity of the acid 
Band 12 dropped to an half, while that of 5 was reduced of only 18%. It 
has to be noted that generally the activity of benzimidazolylbutanoic acids 
is rather long lasting, while that of dehydrocholic acid is pratically estingui-
shed after 2 h from administration. Limiting the comparison of the mean 
activities of DCA and of benzimidazolylbutanoic acids recorded during the 
first two h after administration it must be noted that only the acid 12 
J 







Percent mean variation of bile output at o.s llIlOlIkg 0 
0.25 .cl 1/kg iHl 
, 
(+ 1670/0) was more active than DCA (+ 154%) (Table 11), while the remain-
ing ten more active acids previously mentioned still exhibited high activi-
ties with a bile output mean increase after 2h ranging from + 149 to + 104% 
of the basal value. 
The increase of bile volume is associated with an increase of the bile 
dry residue (Table Ill), the latter being always lower thus indicating that 
the bile is generally more diluted than the basal one. It is noteworthy our 
finding that the tested acids are eliminated with the bile, but no attempts 
were made so far to establish if the acids were excreted unchanged or in 
any modified or conjugated form. Assuming that the excreted benzimida-
zole derivatives had the same extinction coefficient of the injected acids we 
observed that the amounts of acids excreted during the four hours of the 
experiment varyed from 52% (B) to 90% (12) of the injected quantity. This 
observation well accounts for an increase of the bile dry residue imputable 
to the excreted acids or their possible conjugation derivatives. As consequence 
we must deduce that a real increase in dry residue is very limited or only 
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apparent. Among the six acids examined (Table III and IV), only B,7 and 
12 were able to produce a significant increase of the bile dry residue and 
deserve a further investigation in order to control any possible variation of 
both bile cholesterol and cholic acid contents. As regard as the structure-
activity relationships it is noteworthy that, with the only exceptions of acids 
12 and 33, all tested compounds are less active than the model acid B. The 
detrimental effects of the substituents on position 5 of the benzimidazole 
ring or on position 4 of the benzyl residue are generally additive. Very pe-
culiar effects were due to methoxy groups. In fact, going from the 4'-
methoxy- to the 3', 4' -dimethoxy derivative the activity is significantly in-
creased, whereas introduction of a third methoxyl cancelled the activity and 
strongly enhanced the toxicity. Similarly a special mention deserve the 5-
methyl benzimidazole derivatives 29-34; in contrast with the general trend 
the introduction of a substituent on position 4' gives rise to compounds more 
active than the 4' -unsubstituted 29, and in the case of compounds 30 and 
33 the activities are also superior to those of the corresponding compounds 
5 and 9, which do not bear substituent on position 5. 
Finally we must remark that 3-aminobutanoic acid and its aryl deriva-
tives 3a and 3c, as well as the two benzimidazole derivatives 35 and 36 were 
scarcely active or pratically inactive. Thus we can assert that both the inte-
grity of the benzimidazole nucleus and the presence of a cumbersome sub-
stituent in its position 2 are important for the expression of the choleretic 
activity. Moreover, the 2-benzylsubstituted benzimidazolyl-butanoic acids 
are, on the whole, more active than the 2-phenyl or 2-pyridil derivatives pre-
viously described (1). 
In conclusion, the finding of new strong and long lasting choleretic 
agents (mainly'of hydrocholeretic type) warrant the study of additional ben-
zimidazolylbutanoic acids to find the optimal substitution pattern. Moreo-
ver, in order to simulate more closely the circumstances under which such 
agents might be used clinically, the most active compounds will be admini-
stered into the animal duodenum via a catheter and the bile collected hour-
ly will be returned to the animal through the same way. 
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